Eventual Medicinal Benefits of Cannabidiol Oil alleviates Doxorubicin-Related Cardiac injuries

Abstract

Cancer and cardiovascular ailments are the two most prevalent diseases in the world. Cardiotoxicity is a feared adverse effect that could restrict how anthracycline are used in therapeutic settings. Without respect to the oncological prognosis, it may have an impact proceeding the survival and feature of being of malignance patients. A sector that remains quickly developing and holds promise intended for the medication of a wide variety of disorders is safe medical delivery using natural products. The present study's objective is assessing the efficacy of Cannabidiol (CBD) in treating Cardiotoxicity brought on by Doxorubicin (DOX). Fifty male Rats of the Sprague-Dawley breed, 150±25g each were alienated into five equal groups. Distilled water was given to Group I. whereas Group II was administered doxorubicin (18 mg/kg bwt) intraperitoneally. Group V was given Trimetazidine (10 mg/kg bwt), Group IV received 1 ml of CBD (26 mg/kg bwt), while Group III received CBD orally. On the eleventh day (IV, V), Doxorubicin (18 mg/kg bwt) was also given to both groups in a single dose. Serum was analyzed for Troponin (I), Ck-MB, ALT, AST, TNF-, and IL-6. The pretreatment and administration of cannabidiol oil caused significant improvement in lowering cardiac enzymes (Troponin I and Ck-MB), ALT, AST and inflammatory markers (TNF- and IL6). In conclusion, an important effect was seen after CBD (26 mg/kg bwt) treatment. Finally, the anti-inflammatory and antioxidant qualities of CBD might be the reason for its putative beneficial properties.